Mototsugu Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mototsugu Tanaka has a total of 359 co-authors. Here are the top co-authors by number of shared publications:
Naobumi Mise
Department of Nephrology, Division of Internal Medicine, Mitsui Memorial Hospital, Tokyo, Japan
13 shared publicationsMutsuhiro Ikuma
Clinical and Translational Research Center Niigata University Medical and Dental Hospital Niigata Japan
9 shared publicationsTokuichiro Sugimoto
8 shared publicationsMasaki Hojo
Kyoto Univ
7 shared publicationsMasaomi Nangaku
Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo, Japan
7 shared publicationsMayumi Idei
Office of New Drug 1 Pharmaceuticals and Medical Devices Agency Tokyo Japan
7 shared publications
Latest Publications
- Open Access
- 15 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70402
In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in Japan
In vitro diagnostics (IVDs) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) played a critical role in the early detection and management of infection, yet regional disparities in their availability remain underexamined. We retrospectively analyzed molecular and antigen IVDs for SARS‐CoV‐2 authorized by the U.S. Food and Drug Administration (FDA) and approved by the Pharmaceuticals and Medical Devices Agency (PMDA)/Ministry of Health, Labour, and Welfare (MHLW) in Japan between 2020 and 2023, using publicly available data. The FDA granted Emergency Use Authorization (EUA) to 373 IVDs (302 molecular and 71 antigen), while the PMDA/MHLW approved 153 IVDs (55 molecular and 98 antigen) under the Priority Review system within the regular approval framework. In the United States (US), authorizations surged in early 2020, whereas in Japan, approvals increased more gradually until mid‐2021. Real‐time polymerase chain reaction and lateral flow immunoassay were the predominant methods for molecular and antigen tests, respectively, in both countries. In Japan, 71% of prescription‐only IVDs were developed by domestic companies, compared with 79% in the US. In summary, a greater number of IVDs for SARS‐CoV‐2 were authorized in the US than were approved in Japan, particularly early in the pandemic. The EUA system in the US facilitated the rapid authorization of IVDs. Japan's Priority Review system enabled rapid approvals, while the newly introduced Emergency Approval system—although not applied to IVDs for SARS‐CoV‐2—may enable more timely approval and distribution of IVDs in future public health emergencies.
- 15 November 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70402
Open AccessIn Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in Japan
In vitro diagnostics (IVDs) for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) played a critical role in the early detection and management of infection, yet regional disparities in their availability remain underexamined. We retrospectively analyzed molecular and antigen IVDs for SARS‐CoV‐2 authorized by the U.S. Food and Drug Administration (FDA) and approved by the Pharmaceuticals and Medical Devices Agency (PMDA)/Ministry of Health, Labour, and Welfare (MHLW) in Japan between 2020 and 2023, using publicly available data. The FDA granted Emergency Use Authorization (EUA) to 373 IVDs (302 molecular and 71 antigen), while the PMDA/MHLW approved 153 IVDs (55 molecular and 98 antigen) under the Priority Review system within the regular approval framework. In the United States (US), authorizations surged in early 2020, whereas in Japan, approvals increased more gradually until mid‐2021. Real‐time polymerase chain reaction and lateral flow immunoassay were the predominant methods for molecular and antigen tests, respectively, in both countries. In Japan, 71% of prescription‐only IVDs were developed by domestic companies, compared with 79% in the US. In summary, a greater number of IVDs for SARS‐CoV‐2 were authorized in the US than were approved in Japan, particularly early in the pandemic. The EUA system in the US facilitated the rapid authorization of IVDs. Japan's Priority Review system enabled rapid approvals, while the newly introduced Emergency Approval system—although not applied to IVDs for SARS‐CoV‐2—may enable more timely approval and distribution of IVDs in future public health emergencies.
- Open Access
- 5 August 2025
- Published by S. Karger AG in Blood Purification
- Vol. 54 (11) , 680-689
Direct Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-Related Amyloidosis
Introduction: Dialysis-related amyloidosis (DRA) is a serious complication in patients undergoing long-term dialysis that leads to conditions such as carpal tunnel syndrome and destructive spondyloarthropathy. Improved removal of the precursor protein β2-microglobulin (β2-m) is considered an effective treatment strategy for DRA. Polymethylmethacrylate (PMMA) membranes have the capacity to adsorb β2-m in dialysis filters, suggesting that direct hemoperfusion with PMMA in addition to standard dialysis may enhance β2-m removal. Methods: This prospective cohort study included 10 patients undergoing hemodialysis, who were diagnosed with DRA. The participants were treated with dialysis filter alone during visit 1, both standard dialysis filter and PMMA cartridges (FT-75, volume 75 cm3) during visits 2–4, and FT-145 PMMA cartridges (volume 145 cm3) during visits 5–7. The removal rates and clearances of β2-m were quantified. We also assessed the removal of α1-microglobulin (α1-m), matrix metalloproteinase-3 (MMP-3), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α), which may be associated with DRA symptoms. Results: PMMA cartridge had increased β2-m removal rates compared to dialysis filter alone for treatment duration of 240 min. Similarly, the removal rates of α1-m and MMP-3 were higher with PMMA cartridges than with dialysis filter alone. β2-m, α1-m, and MMP-3 clearance improved with the addition of PMMA cartridges, depending on the cartridge size. The removal rates of IL-6 and TNF-α were higher with PMMA cartridges than with dialysis filter alone at 30 min, but not at 240 min. Conclusion: Direct hemoperfusion with PMMA is an effective method for removing β2-m in hemodialysis patients with DRA. Beneficial effects were also observed for the removal of α1-m and MMP-3. Further research is required to evaluate the long-term efficacy of this approach in managing DRA.
- 5 August 2025
- Published by S. Karger AG in Blood Purification
- Vol. 54 (11) , 680-689
Open AccessDirect Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-Related Amyloidosis
Introduction: Dialysis-related amyloidosis (DRA) is a serious complication in patients undergoing long-term dialysis that leads to conditions such as carpal tunnel syndrome and destructive spondyloarthropathy. Improved removal of the precursor protein β2-microglobulin (β2-m) is considered an effective treatment strategy for DRA. Polymethylmethacrylate (PMMA) membranes have the capacity to adsorb β2-m in dialysis filters, suggesting that direct hemoperfusion with PMMA in addition to standard dialysis may enhance β2-m removal. Methods: This prospective cohort study included 10 patients undergoing hemodialysis, who were diagnosed with DRA. The participants were treated with dialysis filter alone during visit 1, both standard dialysis filter and PMMA cartridges (FT-75, volume 75 cm3) during visits 2–4, and FT-145 PMMA cartridges (volume 145 cm3) during visits 5–7. The removal rates and clearances of β2-m were quantified. We also assessed the removal of α1-microglobulin (α1-m), matrix metalloproteinase-3 (MMP-3), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α), which may be associated with DRA symptoms. Results: PMMA cartridge had increased β2-m removal rates compared to dialysis filter alone for treatment duration of 240 min. Similarly, the removal rates of α1-m and MMP-3 were higher with PMMA cartridges than with dialysis filter alone. β2-m, α1-m, and MMP-3 clearance improved with the addition of PMMA cartridges, depending on the cartridge size. The removal rates of IL-6 and TNF-α were higher with PMMA cartridges than with dialysis filter alone at 30 min, but not at 240 min. Conclusion: Direct hemoperfusion with PMMA is an effective method for removing β2-m in hemodialysis patients with DRA. Beneficial effects were also observed for the removal of α1-m and MMP-3. Further research is required to evaluate the long-term efficacy of this approach in managing DRA.
- Open Access
- 8 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 544-553
Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
New drug applications (NDAs) in Japan are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Those that pass the review are subsequently subject to deliberation by the Ministry of Health, Labour and Welfare Pharmaceutical Affairs and Food Sanitation Councils (MHLW‐PAFSC), and the MHLW legislatively grants approval based on its positive opinions. However, little is known regarding the relationship between the PMDA review and the MHLW decision. We retrospectively assessed the MHLW decision of NDAs that passed the PMDA review at the initial MHLW‐PAFSC deliberation from 2002 to 2022. The reasoning behind a non‐supportive opinion from the MHLW‐PAFSC and the sponsor's actions to overcome unresolved issues were also documented. A total of 2,117 of 2,153 (98.3%) NDAs that passed the PMDA review were approved at the initial MHLW‐PAFSC deliberation with a positive opinion. The remaining 36 applications were not approved at the initial deliberation and subjected to continued deliberation because of a non‐supportive opinion from the councils, although 29 were finally approved through revision of the application document (24 applications), re‐analysis of the data (1 application), or additional clinical trials (4 applications). Seven applications have not been approved, of which one was refused, four were withdrawn, and two were unknown. The MHLW approves NDAs that passed the PMDA review at the initial deliberation at a high rate, suggesting that NDAs only suitable for approval passed the review and reached the MHLW‐PAFSC deliberation. Only a few NDAs were not approved at the initial deliberation; however, most of them were finally approved.
- 8 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 544-553
Open AccessConcordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
New drug applications (NDAs) in Japan are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Those that pass the review are subsequently subject to deliberation by the Ministry of Health, Labour and Welfare Pharmaceutical Affairs and Food Sanitation Councils (MHLW‐PAFSC), and the MHLW legislatively grants approval based on its positive opinions. However, little is known regarding the relationship between the PMDA review and the MHLW decision. We retrospectively assessed the MHLW decision of NDAs that passed the PMDA review at the initial MHLW‐PAFSC deliberation from 2002 to 2022. The reasoning behind a non‐supportive opinion from the MHLW‐PAFSC and the sponsor's actions to overcome unresolved issues were also documented. A total of 2,117 of 2,153 (98.3%) NDAs that passed the PMDA review were approved at the initial MHLW‐PAFSC deliberation with a positive opinion. The remaining 36 applications were not approved at the initial deliberation and subjected to continued deliberation because of a non‐supportive opinion from the councils, although 29 were finally approved through revision of the application document (24 applications), re‐analysis of the data (1 application), or additional clinical trials (4 applications). Seven applications have not been approved, of which one was refused, four were withdrawn, and two were unknown. The MHLW approves NDAs that passed the PMDA review at the initial deliberation at a high rate, suggesting that NDAs only suitable for approval passed the review and reached the MHLW‐PAFSC deliberation. Only a few NDAs were not approved at the initial deliberation; however, most of them were finally approved.
- Open Access
- 17 October 2024
- Published by Springer Nature in Research Square
Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label randomized controlled trial (the jDAPA-PD study)
Background The effects of dapagliflozin on patients with end-stage kidney disease (ESKD) and chronic heart failure (CHF) who are on peritoneal dialysis (PD) are not well understood. The jDAPA-PD is a proof-of-concept study designed to assess the efficacy and safety of dapagliflozin in such patients in Japan. Methods/design : This is a multicenter, open-label randomized controlled trial conducted on 40 patients with ESKD and CHF on maintenance PD, particularly those who have substantial residual kidney function. Patients who were recently on sodium–glucose cotransporter 2 inhibitors, hemodialysis, or treatment for peritonitis or those who have a daily urine volume of < 500 mL will be excluded from the study. Participants will be randomized in a 1:1 allocation to either the 10 mg dapagliflozin orally once daily or the standard treatment groups. The primary endpoint is the change in extracellular water from baseline to week 24, which will be measured by bioelectrical impedance analysis. The secondary endpoints are all-cause mortality, cardiovascular events, hospitalization, PD discontinuation, and changes in body composition, blood pressure, renal and cardiac function, brain natriuretic peptide, peritoneal function, PD regimen, and weekly fluid removal from baseline to week 24. The safety endpoints are adverse events and adverse drug reactions that occur during the study period. Discussion This study will determine whether the oral administration of 10 mg of dapagliflozin for 24 weeks is effective in fluid control for patients with CHF on PD. The study will also provide evidence of the safety data and multifaceted effects of dapagliflozin in patients on PD. Trial registration : jRCT1031230624 (registered on February 5, 2024)
- 17 October 2024
- Published by Springer Nature in Research Square
Open AccessDapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label randomized controlled trial (the jDAPA-PD study)
Background The effects of dapagliflozin on patients with end-stage kidney disease (ESKD) and chronic heart failure (CHF) who are on peritoneal dialysis (PD) are not well understood. The jDAPA-PD is a proof-of-concept study designed to assess the efficacy and safety of dapagliflozin in such patients in Japan. Methods/design : This is a multicenter, open-label randomized controlled trial conducted on 40 patients with ESKD and CHF on maintenance PD, particularly those who have substantial residual kidney function. Patients who were recently on sodium–glucose cotransporter 2 inhibitors, hemodialysis, or treatment for peritonitis or those who have a daily urine volume of < 500 mL will be excluded from the study. Participants will be randomized in a 1:1 allocation to either the 10 mg dapagliflozin orally once daily or the standard treatment groups. The primary endpoint is the change in extracellular water from baseline to week 24, which will be measured by bioelectrical impedance analysis. The secondary endpoints are all-cause mortality, cardiovascular events, hospitalization, PD discontinuation, and changes in body composition, blood pressure, renal and cardiac function, brain natriuretic peptide, peritoneal function, PD regimen, and weekly fluid removal from baseline to week 24. The safety endpoints are adverse events and adverse drug reactions that occur during the study period. Discussion This study will determine whether the oral administration of 10 mg of dapagliflozin for 24 weeks is effective in fluid control for patients with CHF on PD. The study will also provide evidence of the safety data and multifaceted effects of dapagliflozin in patients on PD. Trial registration : jRCT1031230624 (registered on February 5, 2024)
- Open Access
- 30 April 2024
- Published by Springer Nature in Research Square
Polyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study)
Background Achieving rapid and secure hemostasis of the vascular access point is important for patients undergoing maintenance hemodialysis (HD). We developed a polyacrylic acid-polyvinylpyrrolidone (PAA-PVP) complex that absorbs moisture such as blood or sterilizing solution, forms a hydrogel, and adheres to the body’s surface, thereby exerting a powerful hemostatic effect. This study aims to compare the effect of PAA-PVP complex versus a conventional non-woven fabric pad on hemostasis at the needle puncture vascular access site in patients on HD. Methods This open-label crossover randomized controlled trial will include 50 participants who undergo thrice-weekly HD. Participants in whom hemostasis requires more than 10 min by compression using a conventional pad or who have a severe skin problem at the needle puncture vascular access site will be excluded from the study. Participants will be randomized in a 1:1 ratio to receive either the PAA-PVP complex or conventional pads. Three consecutive weekly hemostatic tests will be performed at 11, 9, 7, 5, 3, and 1 min. The study will employ an individual 3 + 3 design in which participants in whom hemostasis is achieved in all three sessions in a week will be challenged to a shorter time in the three sessions of the next week. Those in whom hemostasis is achieved in two of three sessions will be tested at the same time point in the three sessions of the next week. The study treatment will be terminated if hemostasis is achieved in only one or none of the sessions, and the minimum time with three consecutive successes will be recorded as the hemostasis time. The primary endpoint, the hemostasis time on the arterial side of the vascular access, will be analyzed using mixed-effect models for repeated measures and include the hemostatic technique and group, period, and individual effects as covariates. Discussion The study will provide evidence on whether the PAA-PVP complex reduces hemostasis time of the vascular access compared to conventional pad in patients on HD. Trial registration jRCTs032220597 (Japan Registry of Clinical Trials; registered on January 30, 2023, https://jrct.niph.go.jp/latest-detail/jRCTs032220597)
- 30 April 2024
- Published by Springer Nature in Research Square
Open AccessPolyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study)
Background Achieving rapid and secure hemostasis of the vascular access point is important for patients undergoing maintenance hemodialysis (HD). We developed a polyacrylic acid-polyvinylpyrrolidone (PAA-PVP) complex that absorbs moisture such as blood or sterilizing solution, forms a hydrogel, and adheres to the body’s surface, thereby exerting a powerful hemostatic effect. This study aims to compare the effect of PAA-PVP complex versus a conventional non-woven fabric pad on hemostasis at the needle puncture vascular access site in patients on HD. Methods This open-label crossover randomized controlled trial will include 50 participants who undergo thrice-weekly HD. Participants in whom hemostasis requires more than 10 min by compression using a conventional pad or who have a severe skin problem at the needle puncture vascular access site will be excluded from the study. Participants will be randomized in a 1:1 ratio to receive either the PAA-PVP complex or conventional pads. Three consecutive weekly hemostatic tests will be performed at 11, 9, 7, 5, 3, and 1 min. The study will employ an individual 3 + 3 design in which participants in whom hemostasis is achieved in all three sessions in a week will be challenged to a shorter time in the three sessions of the next week. Those in whom hemostasis is achieved in two of three sessions will be tested at the same time point in the three sessions of the next week. The study treatment will be terminated if hemostasis is achieved in only one or none of the sessions, and the minimum time with three consecutive successes will be recorded as the hemostasis time. The primary endpoint, the hemostasis time on the arterial side of the vascular access, will be analyzed using mixed-effect models for repeated measures and include the hemostatic technique and group, period, and individual effects as covariates. Discussion The study will provide evidence on whether the PAA-PVP complex reduces hemostasis time of the vascular access compared to conventional pad in patients on HD. Trial registration jRCTs032220597 (Japan Registry of Clinical Trials; registered on January 30, 2023, https://jrct.niph.go.jp/latest-detail/jRCTs032220597)
- Open Access
- 23 April 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (4) , e13803
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis
Drug safety communications (DSCs) are essential tools for communicating important postmarket serious drug safety information to healthcare professionals and patients. Previous studies characterized DSCs issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA); however, knowledge about the activities of the Pharmaceuticals and Medical Devices Agency (PMDA)/the Ministry of Health, Labor and Welfare (MHLW) is limited. This study characterized DSCs by the PMDA/MHLW in comparison with previously reported DSCs by the FDA and the EMA. We retrospectively analyzed 37 DSCs of 41 adverse drug reactions (ADRs) for 33 drugs in Japan from 1997 to 2022. Most DSCs were related to non‐oncology drugs (30/37, 81.1%), and the median (interquartile range) time from approval to DSC issuance was 19 (10–51) months. Notably, the regulatory review reports and the latest labels before DSC issuance did not describe 16/28 (57.1%) and 12/37 (32.4%) of the ADRs related to DSCs, respectively. Most DSCs resulted in label revisions (36/37, 97.3%) and seven drugs were eventually withdrawn. Some DSC characteristics are similar among the PMDA/MHLW, the FDA, and the EMA; however, the number, contents, and range of new safety issues addressed by DSCs differ among the three jurisdictions. Our study emphasized the importance of continuous efforts to gather postmarket drug safety information because substantial ADRs that led to DSCs were recognized after approval and were associated with critical label revisions and withdrawals. Future studies are required to address global challenges for regulatory harmonization of safety‐related regulatory actions.
- 23 April 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (4) , e13803
Open AccessPostmarket safety communications on drugs approved in Japan: A 25‐year analysis
Drug safety communications (DSCs) are essential tools for communicating important postmarket serious drug safety information to healthcare professionals and patients. Previous studies characterized DSCs issued by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA); however, knowledge about the activities of the Pharmaceuticals and Medical Devices Agency (PMDA)/the Ministry of Health, Labor and Welfare (MHLW) is limited. This study characterized DSCs by the PMDA/MHLW in comparison with previously reported DSCs by the FDA and the EMA. We retrospectively analyzed 37 DSCs of 41 adverse drug reactions (ADRs) for 33 drugs in Japan from 1997 to 2022. Most DSCs were related to non‐oncology drugs (30/37, 81.1%), and the median (interquartile range) time from approval to DSC issuance was 19 (10–51) months. Notably, the regulatory review reports and the latest labels before DSC issuance did not describe 16/28 (57.1%) and 12/37 (32.4%) of the ADRs related to DSCs, respectively. Most DSCs resulted in label revisions (36/37, 97.3%) and seven drugs were eventually withdrawn. Some DSC characteristics are similar among the PMDA/MHLW, the FDA, and the EMA; however, the number, contents, and range of new safety issues addressed by DSCs differ among the three jurisdictions. Our study emphasized the importance of continuous efforts to gather postmarket drug safety information because substantial ADRs that led to DSCs were recognized after approval and were associated with critical label revisions and withdrawals. Future studies are required to address global challenges for regulatory harmonization of safety‐related regulatory actions.
- Open Access
- 10 May 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (8) , 1289-1293
Conditional early approval for new drug applications in Japan: Current and emerging issues
- 10 May 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (8) , 1289-1293
Open AccessConditional early approval for new drug applications in Japan: Current and emerging issues
- Open Access
- 22 February 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Aortic arch calcification affects causes of death in patients on hemodialysis: a retrospective cohort study
Background: Aortic arch calcification (AAC) is a well-known risk factor for death in patients on hemodialysis (HD); however, the causes of death among them have not been well studied. The study aimed to investigate the distribution of causes of death and long-term prognosis among different degrees of AAC in HD patients. Methods: A retrospective cohort study was conducted on patients undergoing HD at two clinics in Japan. AAC grades 0 to 3 were categorized by chest radiograph at baseline, and mortality and causes of death were collected. A subgroup analysis was performed to evaluate the relationship between causes of death and age, diabetes mellitus, and dialysis vintage in each AAC grade. Results: A total of 321 patients were included in the analysis. During 5.2 ± 2.1 years, 117 patients died, and the death rates in AAC grades 0, 1, 2, and 3 were 19.3% (17/88), 35.2% (51/145), 46.3% (25/54), and 70.6% (24/34), respectively. The major causes of death were cardiovascular disease (CVD, 39.3%), infection (20.5%), and malignancy (15.4%) in the entire cohort. In AAC grade 3, CVD mortality (33.3%) remains as the most common cause of death, although death of infection (29.2%) and malnutrition (16.7%) increased markedly. A subgroup analysis showed that AAC grade 3 was mostly old, non-diabetic patients with a long dialysis vintage and was susceptible to death of infection or malnutrition. Conclusions: CVD was the most common cause of death among all AAC grades, although death of infection and malnutrition markedly increased in those with severe AAC. Attention should be paid to CVD, infection, and malnutrition in HD patients with severe AAC.
- 22 February 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Open AccessAortic arch calcification affects causes of death in patients on hemodialysis: a retrospective cohort study
Background: Aortic arch calcification (AAC) is a well-known risk factor for death in patients on hemodialysis (HD); however, the causes of death among them have not been well studied. The study aimed to investigate the distribution of causes of death and long-term prognosis among different degrees of AAC in HD patients. Methods: A retrospective cohort study was conducted on patients undergoing HD at two clinics in Japan. AAC grades 0 to 3 were categorized by chest radiograph at baseline, and mortality and causes of death were collected. A subgroup analysis was performed to evaluate the relationship between causes of death and age, diabetes mellitus, and dialysis vintage in each AAC grade. Results: A total of 321 patients were included in the analysis. During 5.2 ± 2.1 years, 117 patients died, and the death rates in AAC grades 0, 1, 2, and 3 were 19.3% (17/88), 35.2% (51/145), 46.3% (25/54), and 70.6% (24/34), respectively. The major causes of death were cardiovascular disease (CVD, 39.3%), infection (20.5%), and malignancy (15.4%) in the entire cohort. In AAC grade 3, CVD mortality (33.3%) remains as the most common cause of death, although death of infection (29.2%) and malnutrition (16.7%) increased markedly. A subgroup analysis showed that AAC grade 3 was mostly old, non-diabetic patients with a long dialysis vintage and was susceptible to death of infection or malnutrition. Conclusions: CVD was the most common cause of death among all AAC grades, although death of infection and malnutrition markedly increased in those with severe AAC. Attention should be paid to CVD, infection, and malnutrition in HD patients with severe AAC.
- 28 December 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 1014-1022
Effluent N‐terminal expressed in renal cell carcinoma/mesothelin predicts increased peritoneal permeability in patients undergoing peritoneal dialysis
Introduction: We investigated whether N‐terminal and C‐terminal products of expressed in renal cell carcinoma/mesothelin (N‐ERC and C‐ERC) in peritoneal effluent can predict peritoneal permeability in patients undergoing peritoneal dialysis (PD).Methods: Thirty‐seven peritoneal effluent samples were obtained from 26 PD patients. High transport status was determined by the peritoneal equilibration test as a dialysate/plasma ratio of creatinine (D/P Cr) ≥ 0.81. Effluent cancer antigen 125 (CA125) was used as a reference.Results: Effluent N‐ERC concentration was better correlated with D/P Cr than effluent C‐ERC or CA125 concentration. In multivariate analyses, effluent N‐ERC and C‐ERC, but not CA125, were significant predictors of high transport status after adjusting for age, PD duration, and residual renal Kt/V. ROC analysis showed that effluent N‐ERC was the best predictor of high transport status among those three biomarkers.Conclusion: Effluent N‐ERC predicts increased peritoneal permeability in patients undergoing PD.
- 28 December 2021
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (5) , 1014-1022
Effluent N‐terminal expressed in renal cell carcinoma/mesothelin predicts increased peritoneal permeability in patients undergoing peritoneal dialysis
Introduction: We investigated whether N‐terminal and C‐terminal products of expressed in renal cell carcinoma/mesothelin (N‐ERC and C‐ERC) in peritoneal effluent can predict peritoneal permeability in patients undergoing peritoneal dialysis (PD).Methods: Thirty‐seven peritoneal effluent samples were obtained from 26 PD patients. High transport status was determined by the peritoneal equilibration test as a dialysate/plasma ratio of creatinine (D/P Cr) ≥ 0.81. Effluent cancer antigen 125 (CA125) was used as a reference.Results: Effluent N‐ERC concentration was better correlated with D/P Cr than effluent C‐ERC or CA125 concentration. In multivariate analyses, effluent N‐ERC and C‐ERC, but not CA125, were significant predictors of high transport status after adjusting for age, PD duration, and residual renal Kt/V. ROC analysis showed that effluent N‐ERC was the best predictor of high transport status among those three biomarkers.Conclusion: Effluent N‐ERC predicts increased peritoneal permeability in patients undergoing PD.
- 1 July 2021
- Published by Elsevier in Kidney International
- Vol. 100 (1) , 241-242
The PMDA’s view on the limited pipeline of nephrology drugs in Japan
- 1 July 2021
- Published by Elsevier in Kidney International
- Vol. 100 (1) , 241-242
The PMDA’s view on the limited pipeline of nephrology drugs in Japan